Leukemia clinical trials in Nevada

11 actively recruiting leukemia trials at 5 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Network

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …

Sponsor: Children's Oncology Group

NCT ID: NCT05602194

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
OptumCare Cancer Care at Seven Hills — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Southeast Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…

Sponsor: PedAL BCU, LLC

NCT ID: NCT05183035

Sites in Nevada:

Alliance for Childhood Diseases dba Cure 4 The Kids Foundation — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564390

Sites in Nevada:

OptumCare Cancer Care at Seven Hills — Henderson, Nevada
OptumCare Cancer Care at Charleston — Las Vegas, Nevada
OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03739814

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554406

Sites in Nevada:

OptumCare Cancer Care at Seven Hills — Henderson, Nevada
OptumCare Cancer Care at Charleston — Las Vegas, Nevada
OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04546399

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada
OptumCare Cancer Care at Seven Hills — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554393

Sites in Nevada:

OptumCare Cancer Care at Seven Hills — Henderson, Nevada
OptumCare Cancer Care at Charleston — Las Vegas, Nevada
OptumCare Cancer Care at Fort Apache — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC

NCT ID: NCT04726241

Sites in Nevada:

Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
Summerlin Hospital Medical Center — Las Vegas, Nevada
Renown Regional Medical Center — Reno, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…

Sponsor: Loxo Oncology, Inc.

NCT ID: NCT06588478

Sites in Nevada:

Comprehensive Cancer Centers of Nevada — Henderson, Nevada

View on ClinicalTrials.gov →

Recruiting Network

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…

Sponsor: Children's Oncology Group

NCT ID: NCT01790152

Sites in Nevada:

University Medical Center of Southern Nevada — Las Vegas, Nevada
Sunrise Hospital and Medical Center — Las Vegas, Nevada
Alliance for Childhood Diseases/Cure 4 the Kids Foundation — Las Vegas, Nevada
Summerlin Hospital Medical Center — Las Vegas, Nevada

View on ClinicalTrials.gov →

Recruiting Industry

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and th…

Sponsor: Tempus AI

NCT ID: NCT07154823

Sites in Nevada:

Cancer Care Specialists of Reno — Reno, Nevada

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20